BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DHI Global Medical Group Adopts BioLife Solutions, Inc. (BLFS.OB)' HypoThermosol® as Improved Hair Graft Storage Medium


1/8/2013 9:34:49 AM

BOTHELL, Wash., Jan. 8, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today announced that DHI Global Medical Group has adopted BioLife's proprietary HypoThermosol cell/tissue storage and shipping medium to improve ex-vivo survival of hair grafts during transplantation procedures.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Mike Rice, BioLife Solutions Chief Executive Officer, said, "We have spent the past few years building the value of HypoThermosol as an important biopreservation medium in hair restoration and we believe 2013 will be the year that this market becomes a significant revenue stream for BioLife Solutions. We are very pleased to support DHI Global in its continuous quality improvement initiative. DHI Global joins a growing number of hair restoration clinicians and professionals who understand the value and benefits of transitioning from non-optimized graft storage solutions to using HypoThermosol, which is engineered to better protect cells and tissues exposed to hypothermic biopreservation conditions. Leading hair restoration surgeons around the world have adopted HypoThermosol after seeing improved graft survival and increased patient satisfaction."

DHI Global used volumes of HypoThermosol in its offices in Paris, London, and Athens, with a goal of establishing use of HypoThermosol as a standard of care through its network of more than 30 global locations.

The International Society of Hair Restoration Surgery (ISHRS) estimates that nearly 300,000 surgical hair restoration procedures were performed worldwide in 2010.

About DHI Global Medical Group

Founded in 1970 with now over 30 worldwide affiliated locations, DHI Global Medical Group hair restoration professionals have performed over 150,000 procedures. The company was founded by Mr. K.P. Giotis in Palo Alto, California and has been dedicated solely to the research, diagnosis and treatment of hair and scalp disorders. 42 years later, the DHI technique offers hair loss sufferers across the globe a painless procedure with natural results. For more information please visit www.dhiglobal.com.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation media products for cells and tissues. The Company's proprietary HypoThermosol® and CryoStor® biopreservation media products are marketed to academic and commercial organizations involved in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media Relations:

Investor Relations:


Len Hall

Matt Clawson


Allen & Caron Inc

Allen & Caron Inc


(949) 474-4300

(949) 474-4300


len@allencaron.com

matt@allencaron.com





SOURCE BioLife Solutions, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES